65865-25-0Relevant academic research and scientific papers
LIVER X RECEPTORS (LXR) MODULATORS
-
Page/Page column 79-80, (2018/11/22)
The present invention relates to sulfonamide-, sulfinamide- or sulfonimidamide containing compounds which bind to the liver X receptor (LXRa and/or LXR?) and act preferably as inverse agonists of LXR.
Discovery of sulfonamidebenzamides as selective apoptotic CHOP pathway activators of the unfolded protein response
Flaherty, Daniel P.,Miller, Justin R.,Garshott, Danielle M.,Hedrick, Michael,Gosalia, Palak,Li, Yujie,Milewski, Monika,Sugarman, Eliot,Vasile, Stefan,Salaniwal, Sumeet,Su, Ying,Smith, Layton H.,Chung, Thomas D. Y.,Pinkerton, Anthony B.,Aub, Jeffrey,Callaghan, Michael U.,Golden, Jennifer E.,Fribley, Andrew M.,Kaufman, Randal J.
supporting information, p. 1278 - 1283 (2015/01/09)
Cellular proteins that fail to fold properly result in inactive or disfunctional proteins that can have toxic functions. The unfolded protein response (UPR) is a two-tiered cellular mechanism initiated by eukaryotic cells that have accumulated misfolded p
Inhibition of HIV-1 capsid assembly: Optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol- 1-yl)-1H-benzimidazole scaffold
Tremblay, Martin,Bonneau, Pierre,Bousquet, Yves,Deroy, Patrick,Duan, Jianmin,Duplessis, Martin,Gagnon, Alexandre,Garneau, Michel,Goudreau, Nathalie,Guse, Ingrid,Hucke, Oliver,Kawai, Stephen H.,Lemke, Christopher T.,Mason, Stephen W.,Simoneau, Bruno,Surprenant, Simon,Titolo, Steve,Yoakim, Christiane
, p. 7512 - 7517 (2013/02/23)
A uHTS campaign led to the discovery of a 5-(5-furan-2-ylpyrazol-1-yl)-1H- benzimidazole series that inhibits assembly of HIV-1 capsid. Synthetic manipulations at N1, C2 and C16 positions improved the antiviral potency by a. The X-ray structure of 33 complexed with the capsid N-terminal domain allowed identification of major interactions between the inhibitor and the protein.
